Abstract | BACKGROUND: METHODS: In this retrospective study, HCC patients with PVTT received either induction therapy of HAIC and lenvatinib plus PD1s in the initial period of treatment and then dual maintenance therapy of lenvatinib and PD1s (HAIC-Len-PD1) or continuous lenvatinib combined with PD1s (Len-PD1). RESULTS: In total, 53 and 89 patients were enrolled into the Len-PD1 group and HAIC-Len-PD1 group, respectively. The median overall survival times were 13.8 months in the Len-PD1 group and 26.3 months in the HAIC-Len-PD1 group (hazard ratio (HR) = 0.43, P < 0.001). The median progression-free survival (PFS) time was significantly longer in the HAIC-Len-PD1 group than in the Len-PD1 group (11.5 months versus 5.5 months, HR = 0.43, P < 0.001). Induction therapy showed an objective response rate (ORR) 3 times higher than lenvatinib combined with PD1s therapy (61.8% versus 20.8%, P < 0.001), and exhibited inspiring intra- and extra-hepatic tumor control ability. Induction therapy led to more adverse events than lenvatinib combined with PD1s therapy, most of which were tolerable and controllable. CONCLUSION: The induction therapy of FOLFOX-HAIC and lenvatinib plus PD1s is an effective and safe treatment for HCC patients with PVTT. The concept of induction therapy could be applied to other local-regional treatments and drugs combinations in HCC management.
|
Authors | Yizhen Fu, Wei Peng, Weixiang Zhang, Zhenyun Yang, Zili Hu, Yanxun Pang, Dandan Hu, Jinbin Chen, Juncheng Wang, Zhongguo Zhou, Li Xu, Minshan Chen, Yaojun Zhang |
Journal | Journal of gastroenterology
(J Gastroenterol)
Vol. 58
Issue 4
Pg. 413-424
(04 2023)
ISSN: 1435-5922 [Electronic] Japan |
PMID | 36894804
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2023. Japanese Society of Gastroenterology. |
Chemical References |
|
Topics |
- Humans
- Carcinoma, Hepatocellular
(complications, drug therapy, pathology)
- Liver Neoplasms
(complications, drug therapy, pathology)
- Portal Vein
(pathology)
- Retrospective Studies
- Induction Chemotherapy
- Treatment Outcome
- Infusions, Intra-Arterial
- Fluorouracil
(adverse effects)
- Venous Thrombosis
(drug therapy, etiology, pathology)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
|